Cargando…
Multiple treatment comparisons in epilepsy monotherapy trials
BACKGROUND: The choice of antiepileptic drug for an individual should be based upon the highest quality evidence regarding potential benefits and harms of the available treatments. Systematic reviews and meta-analysis of randomised controlled trials should be a major source of evidence supporting th...
Autores principales: | Tudur Smith, Catrin, Marson, Anthony G, Chadwick, David W, Williamson1, Paula R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194733/ https://www.ncbi.nlm.nih.gov/pubmed/17983480 http://dx.doi.org/10.1186/1745-6215-8-34 |
Ejemplares similares
-
Time to 12-month remission and treatment failure for generalised and unclassified epilepsy
por: Bonnett, Laura J, et al.
Publicado: (2014) -
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child
por: Bromley, Rebecca, et al.
Publicado: (2023) -
The trials and tribulations of accessing data from routine sources
por: Powell, Graham, et al.
Publicado: (2015) -
Importance of competing risks in the analysis of anti-epileptic drug failure
por: Williamson, Paula R, et al.
Publicado: (2007) -
Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II)
por: Balabanova, Silviya, et al.
Publicado: (2020)